Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-2020S immunogenicity and safety in adults for COVID-19
NCT04950751Phase 2Withdrawn
- Sponsor
- Clover Biopharmaceuticals
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of SCB-2020S in coronavirus disease 2019 (COVID-19), sponsored by Clover Biopharmaceuticals. Planned start Aug 2021; status: withdrawn.
02
Drugs
SCB-2020S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04950751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950751.